JUL 22·SEC EDGARLow
Giroux Richard sold $701K of MGTX
Giroux Richard (CFO & COO) sold 56,000 shares of MeiraGTx Holdings plc (MGTX) at $12.51 ($0.70M total) on 2026-07-21 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Biotechnology
$MGTX
MeiraGTx Holdings plc
Price · $MGTXvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $MGTX in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $701K 1 txs
Giroux Richard1× · $701K
10b5-1 plan100%
Top stories · $MGTXMore →
JUL 8·bioxconomy.com
MeiraGTx secures $400m from Oberland Capital
MeiraGTx said it will receive up to $375m in non-dilutive capital from Oberland Capital via capped royalties, plus up to $25m in equity. An initial $135m was funded, including $125m in low single-digit royalties and a $10m equity stake. Additional payments total $150m tied to Phase II completion and regulatory approvals for AAV2-hAQP1 and bota-vec.
JUL 7·manilatimes.net
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
MeiraGTx Holdings (Nasdaq: MGTX) said it agreed with Oberland Capital for up to $400m to fund development/commercialization of AAV2-hAQP1 (RIX), bota-vec (XLRP) and AAV-AIPL1. Oberland will provide up to $375m in non-dilutive capped royalty funding and up to $25m equity, with additional tranches tied to 2027–2028 data/approvals.
MGTX sentiment & insider activity
Recent MGTX coverage spans financial news, corporate actions and insider activity.
In the last 30 days, MGTX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($701K). The most active reporter was Giroux Richard, CFO & COO, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
What's driving MGTX
Routine 10b5-1 insider sale provides limited signal, but it can slightly affect near-term sentiment and liquidity expectations.
The financing reduces dilution risk and ties cash inflows to Phase II completion and regulatory approvals for bota-vec and AAV2-hAQP1.
The financing structure reduces dilution risk while tying additional capital to 2027–2028 clinical/regulatory milestones, likely improving near-term funding visibility and risk perception.
The filing signals a new secured financing structure (royalty note purchase) that can change near-term liquidity, leverage optics, and covenant risk.
Routine shareholder-meeting outcomes; no operational or financial guidance changes disclosed.
alphai scores every news story that mentions MGTX with an AI model for sentiment and relevance, and aggregates insider trades from MeiraGTx Holdings plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $MGTX
Score
Giroux Richard sold $701K of MGTX
Giroux Richard (CFO & COO) sold 56,000 shares of MeiraGTx Holdings plc (MGTX) at $12.51 ($0.70M total) on 2026-07-21 under a Rule 10b5-1 trading plan.
1 min read
MeiraGTx secures $400m from Oberland Capital
MeiraGTx said it will receive up to $375m in non-dilutive capital from Oberland Capital via capped royalties, plus up to $25m in equity. An initial $135m was funded, including $125m in low single-digit royalties and a $10m equity stake. Additional payments total $150m tied to Phase II completion and regulatory approvals for AAV2-hAQP1 and bota-vec.
4 min read
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
MeiraGTx Holdings (Nasdaq: MGTX) said it agreed with Oberland Capital for up to $400m to fund development/commercialization of AAV2-hAQP1 (RIX), bota-vec (XLRP) and AAV-AIPL1. Oberland will provide up to $375m in non-dilutive capped royalty funding and up to $25m equity, with additional tranches tied to 2027–2028 data/approvals.
4 min readMeiraGTx Holdings plc (MGTX): Entry into a Material Definitive Agreement
MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 mgtx-20260630xex10d1.htm EX-10.1 Exhibit 10.1 Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. Execution Version ROYALTY NOTE PUR
6 min readMeiraGTx Holdings plc (MGTX): Submission of Matters to a Vote of Security Holders
MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. MeiraGTx Holdings plc_June 11, 2026 0001735438 false 0001735438 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of
2 min read
MeiraGTx Holdings stock (US58550P1012): Insider selling draws attention as gene therapy story evolve
MeiraGTx Holdings is a gene therapy specialist focused on inherited retinal diseases and neurology, operating a vertically integrated platform with its own manufacturing facilities. CEO Alexandria Forbes recently sold 62,000 shares, adding to the stock's volatility. Despite the insider sale, the company's long-term value is expected to be driven primarily by progress in clinical trials, regulatory milestones, and collaboration advancements.
4 min read
MeiraGTx Holdings PLC (NASDAQ:MGTX) Given Average Rating of "Moderate Buy" by Analysts
MeiraGTx Holdings PLC has received a "Moderate Buy" average rating from six research firms, with an average 12-month price target of $26.00. Despite analyst optimism, the company reported weaker-than-expected quarterly earnings, missing EPS estimates and showing low revenue. Insider selling by the CEO and CFO has also occurred, contrasting with institutional investors who hold a significant portion of the company's stock.
3 min read
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Lags Revenue Estimates
MeiraGTx (MGTX) delivered earnings and revenue surprises of -24.00% and -89.95%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min read
Eli Lilly Expands Genetic Eye-Disease Focused Pipeline With MeiraGTx Gene Therapy Collaboration - Eli Lilly (NYSE:LLY), MeiraGTx Hldgs (NASDAQ:MGTX)
MeiraGTx Holdings plc ( NASDAQ:MGTX ) stock is trading higher after the company inked a strategic collaboration in the area of ophthalmology with Eli Lilly and Co. ( NYSE:LLY ) .
3 min read
MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
MeiraGTx (MGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 min read